Takeda shoots down bispecifics bagged in Maverick buyout amid pipeline clearout
Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R&D pipeline in the process. The two terminations, coupled to the removal of a third asset, halved the number of cancer candidates in Takeda’s phase 1 and 2 pipeline.
Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R&D pipeline in the process. The two terminations, coupled to the removal of a third asset, halved the number of cancer candidates in Takeda’s phase 1 and 2 pipeline.
